Pharmacy Website
    Clinic Website

    Intelligence » Hepatitis B » Last Week

    Subscribe to get latest posts via email or subscribe to a RSS feed.

    GILEAD SCIENCES, INC: Hookipa and Gilead Enter into a Collaboration and License Agreement to Develop Immunotherapies Against HIV and Hepatitis B

    Wednesday, June 20, 2018 -- Hookipa Biotech AG ("Hookipa"), a clinical-stage biotech company pioneering an innovative class of active immunization therapies for oncology and infectious diseases and Gilead Sciences, Inc., ("Gilead"), a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need, today announced that they have entered into a research collaboration and license agreement that grants Gilead exclusive rights to Hookipa's TheraT® and Vaxwave® arenavirus vector-based immunization technologies for two major chronic infectious disease indications, hepatitis B virus (HBV) and human immunodeficiency virus (HIV). Read more..

    Normal on-Treatment ALT Linked to Reduced Hepatic Events in Hepatitis B

    Thursday, June 21, 2018 -- Patients with chronic hepatitis B have a lower risk of hepatic events if they achieve normal on-treatment ALT in the first 12 months of NA treatment.

    Hepatitis B screening remains important prior to anticancer therapy

    Monday, June 18, 2018 -- Jessica P. HwangAlthough a risk assessment tool can identify patients with cancer who are at risk for hepatitis B virus (HBV) reactivation from anticancer therapy, most patients will still require HBV testing, according to study results.“This study is the first to provide strong data to help determine optimal HBV screening strategies for patients with cancer,” Jessica P. Hwang, MD, MPH, associate professor in the department of general internal medicine at The University of Texas MD Anderson Cancer Center, told HemOnc Today. “Our findings may have implications for HBV

    Combination HBV therapy shows functional control 24 weeks after cessation

    Monday, June 18, 2018 -- Replicor recently shared follow-up data from the ongoing REP 401 trial that showed high rates of persistent functional control of hepatitis B after cessation of therapy with REP 2139-Mg or REP 2165-Mg plus pegylated interferon alpha-2a and tenofovir disoproxil fumarate, according to a press release.“REP 2139’s ability to rapidly reduce [HBV surface antigen] in 90% of patients is unique in the industry and is accompanied by immediate reductions of viremia in the blood and viral replication in the liver,” Andrew Vaillant, PhD, chief scientific officer at Replicor, said in the